A Phase I, 2-Part, Open-label, Multiple Oral Dose Study of the Safety, Tolerability and Pharmacokinetics of up to 2 Formulations of SMT C1100 in Healthy Adult Male Subjects and a Selected Formulation of SMT C1100 in Paediatric Subjects with Duchenne Muscular Dystrophy (DMD)

Trial Profile

A Phase I, 2-Part, Open-label, Multiple Oral Dose Study of the Safety, Tolerability and Pharmacokinetics of up to 2 Formulations of SMT C1100 in Healthy Adult Male Subjects and a Selected Formulation of SMT C1100 in Paediatric Subjects with Duchenne Muscular Dystrophy (DMD)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2018

At a glance

  • Drugs Ezutromid (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Pharmacokinetics
  • Most Recent Events

    • 27 Jun 2018 According to a Summit Therapeutics media release, based on the results of the PhaseOut DMD 48-week data, the company has discontinued this drug development program, as, its primary and secondary endpoints has not been Met.
    • 27 Jun 2018 Status changed from active, no longer recruiting to discontinued, according to a Summit Therapeutics media release.
    • 22 Jun 2017 According to a Summit Therapeutics media release, data from this trial will be presented at the European Paediatric Neurology Society Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top